LRRK2 in Parkinson's disease: genetic and clinical studies from patients.
about
MAP1B rescues LRRK2 mutant-mediated cytotoxicityLRRK2 functions as a Wnt signaling scaffold, bridging cytosolic proteins and membrane-localized LRP6A direct interaction between leucine-rich repeat kinase 2 and specific β-tubulin isoforms regulates tubulin acetylationAlpha-synuclein Toxicity in the Early Secretory Pathway: How It Drives Neurodegeneration in Parkinsons DiseaseThe complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson's diseaseThe regulation and deregulation of Wnt signaling by PARK genes in health and diseaseThe role of the LRRK2 gene in ParkinsonismExploring the Effects of Genetic Variants on Clinical Profiles of Parkinson's Disease Assessed by the Unified Parkinson's Disease Rating Scale and the Hoehn-Yahr StageProtective LRRK2 R1398H Variant Enhances GTPase and Wnt Signaling Activity.Cerebrospinal fluid amyloid β and tau in LRRK2 mutation carriersRole of LRRK2 kinase dysfunction in Parkinson diseaseThe genetic background of Parkinson's disease: current progress and future prospects.Non-motor and motor features in LRRK2 transgenic mice.Evaluating LRRK2 genetic variants with unclear pathogenicity.Genetic causes of Parkinson's disease in the Maltese: a study of selected mutations in LRRK2, MTHFR, QDPR and SPRThe role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's diseasePremotor biomarkers for Parkinson's disease - a promising direction of research.Dopaminergic expression of the Parkinsonian gene LRRK2-G2019S leads to non-autonomous visual neurodegeneration, accelerated by increased neural demands for energy.LRRK2: an éminence grise of Wnt-mediated neurogenesis?ULK1 and JNK are involved in mitophagy incurred by LRRK2 G2019S expression.LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease.LRRK2 regulates retrograde synaptic compensation at the Drosophila neuromuscular junction.Drosophila Mutant Model of Parkinson's Disease Revealed an Unexpected Olfactory Performance: Morphofunctional Evidences.Next-generation sequencing in understanding complex neurological diseasePathogenic LRRK2 variants are gain-of-function mutations that enhance LRRK2-mediated repression of β-catenin signalingLRRK2 in Parkinson's disease: function in cells and neurodegeneration.Development of Parkinson's disease biomarkers.A tangled web - tau and sporadic Parkinson's diseaseTargeting leucine-rich repeat kinase 2 in Parkinson's disease.New insight into neurodegeneration: the role of proteomics.LRRK2 and neuroinflammation: partners in crime in Parkinson's disease?Promising Targets for the Treatment of Neurodegenerative Diseases.Alpha-synuclein: relating metals to structure, function and inhibition.Early synaptic dysfunction in Parkinson's disease: Insights from animal models.Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Does any drug to treat cancer target mTOR and iron hemostasis in neurodegenerative disorders?Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models.Direct interaction of α-synuclein and AKT regulates IGF-1 signaling: implication of Parkinson disease.Structural and functional in silico analysis of LRRK2 missense substitutions.Polymer brain-nanotherapeutics for multipronged inhibition of microglial α-synuclein aggregation, activation, and neurotoxicity.
P2860
Q24295033-F0FE65BE-D0AC-4568-BAF9-D8C41E67B3ADQ24296778-8870937F-A7E8-4326-BFEB-0CCA0CF7A333Q24310126-B76945DE-2F2E-42CF-A437-80047F14066BQ26776209-3CF220AB-0978-4C57-B878-019A846F38FDQ26853537-051E87E6-6C4B-439A-BCA6-924613BAA6BDQ26991986-89E4B08E-0E93-4409-A13B-16CDC60B34FCQ27023749-FA0358FF-ECC8-421A-85DE-429C55C1226DQ28396892-4419A517-AE62-4E35-AD36-F265AFD30E1CQ29347547-6A6E53BE-61C8-49C5-AE60-3EF4CEAFF8F5Q30525550-0FDA117F-220D-4B99-81A9-C4F8520929FAQ34192817-B412DEF3-50AD-4189-80FA-A6474965BFE2Q34513714-E3EA3D5A-20AD-4262-9ED1-471EECC17186Q34922393-474AE699-5293-49EB-929C-379EDF3255B7Q35187769-10E95A52-B311-49E4-8EBD-9E148A261084Q36128958-F30E29DB-EC05-4EB6-8340-744C0CB65D97Q36325701-9F9404BC-391F-46C1-884F-EF42EB9863E7Q36444517-2B13CCF7-CD77-4191-8595-944274B3764EQ36839019-00AF5353-EBBB-4050-BF06-29C2A5CA4816Q36888947-C3E408DA-445B-4598-B30F-E947125C855EQ36923141-9852A5FB-5FCF-4FFC-A4BA-8DAF7BF5E5A8Q36981223-985800D0-0C44-4EEA-8BD5-3994C9F8045EQ37124577-0C2EBD09-A969-41B5-85A1-BD33B0BCD293Q37246534-C389F7FC-3068-41D6-8FC1-1E4F1FD1C286Q37331388-3E955655-C0A0-4BA5-BE52-5651BE73A8F8Q37595673-2F8EA9E3-799E-4F84-B98B-840561438D49Q37608630-F1B64FA2-BD2A-4F23-889E-261CB6CF5D82Q37810992-7D0D4204-F69D-4CC3-BDFF-A6948E28DCF2Q37855547-CAC1D408-00B4-4740-AFEC-81E326E0B9DBQ38160939-D061EEA6-BDFF-4200-8464-AEFAE2A847FAQ38170010-EB8FC5E5-2119-4038-A2A2-5EE15A786085Q38198207-E90C866D-5C85-4F63-B5E7-70D80AB5ED7CQ38562084-9CF757B9-5F80-4247-B3E1-0D3EEAECDA72Q38728563-439E7EC7-4420-4DD6-8857-51D6A7B15685Q38837604-AE019C5E-45F4-4344-AD10-81EAFE8F1B30Q39002226-1C07D751-3EBD-41E3-87AD-98CF40B7F4D8Q39010650-E9C04A0E-3B90-4DFB-8A82-316C10B4684DQ39164937-E03F2CCA-E3A5-4ED2-9120-C052BA0927A0Q39562119-A59173C7-5A2D-4992-971F-153683006D27Q45143202-E50B9BB3-B49E-4EB1-A7DB-BF8DE59B62DFQ45814729-745A1900-7EAA-4FD0-BBD8-A9FADAE172F5
P2860
LRRK2 in Parkinson's disease: genetic and clinical studies from patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
LRRK2 in Parkinson's disease: genetic and clinical studies from patients.
@en
LRRK2 in Parkinson's disease: genetic and clinical studies from patients.
@nl
type
label
LRRK2 in Parkinson's disease: genetic and clinical studies from patients.
@en
LRRK2 in Parkinson's disease: genetic and clinical studies from patients.
@nl
prefLabel
LRRK2 in Parkinson's disease: genetic and clinical studies from patients.
@en
LRRK2 in Parkinson's disease: genetic and clinical studies from patients.
@nl
P2860
P1433
P1476
LRRK2 in Parkinson's disease: genetic and clinical studies from patients.
@en
P2093
Udhaya Kumari
P2860
P304
P356
10.1111/J.1742-4658.2009.07344.X
P407
P577
2009-10-05T00:00:00Z